Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCPCS codes

This article was originally published in The Gray Sheet

Executive Summary

CMS proposed to establish six new durable medical equipment, prosthetic, orthotic and supply (DMEPOS) codes in 2011 out of 87 new Healthcare Common Procedure Coding System code requests in the lead-up to a series of public HCPCS coding meetings convening this week through early June. If CMS sticks with its preliminary decisions, new unique codes would be available for two outpatient accessories used with Thoratec's HeartMate II left-ventricular assist device, a component of Cochlear's Baha implantable hearing loss treatment system, EO2 Concepts' TransCu O2 electrochemical low-dose tissue oxygenation wound treatment system, a component of Philips/Respironics' CoughAssist device for removing secretions in patients who lack the ability to cough effectively, and Ermi's MPJ Extensionater therapy machine for accelerating recovery of a joint in the toe. Requestors for the other 81 new codes will have a chance to argue their case at the upcoming meetings at CMS headquarters in Baltimore. The agency will issue final decisions by year-end

You may also be interested in...



BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   

US OTC Switch Drought Ends: FDA Approves GSK Arthritis Gel, Alcon Allergy Eye Drops

FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.

Topics

UsernamePublicRestriction

Register

MT028913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel